Compugen Ltd. (CGEN)
Nasdaq · Healthcare · Biotechnology
$2.310.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $219M
- P/E (trailing)
- 6.1
- 52-week range
- $1.43 – $3.24
- 52-week change
- +31.25%
- EPS (trailing)
- $0.38
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $72.8M (+161.14%)
- Net income
- $35.3M
- Operating margin
- 43.1%
- Diluted EPS
- $0.38
- Free cash flow
- $31.3M
From the company’s annual report on SEC EDGAR.
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
Headquarters: Holon, Israel · 75 employees · cgen.com